ELMD vs. OM, SMLR, FONR, VANI, HYPR, AXGN, MOVE, ECOR, EDAP, and ZYXI
Should you be buying Electromed stock or one of its competitors? The main competitors of Electromed include Outset Medical (OM), Semler Scientific (SMLR), FONAR (FONR), Vivani Medical (VANI), Hyperfine (HYPR), AxoGen (AXGN), Movano (MOVE), electroCore (ECOR), Edap Tms (EDAP), and Zynex (ZYXI). These companies are all part of the "electromedical equipment" industry.
Outset Medical (NASDAQ:OM) and Electromed (NYSE:ELMD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, media sentiment, profitability, community ranking, dividends, analyst recommendations, institutional ownership, earnings and risk.
Electromed has a net margin of 8.14% compared to Electromed's net margin of -134.93%. Outset Medical's return on equity of 10.97% beat Electromed's return on equity.
In the previous week, Outset Medical had 6 more articles in the media than Electromed. MarketBeat recorded 7 mentions for Outset Medical and 1 mentions for Electromed. Outset Medical's average media sentiment score of 0.00 beat Electromed's score of -0.11 indicating that Electromed is being referred to more favorably in the news media.
Outset Medical has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500. Comparatively, Electromed has a beta of 0.4, suggesting that its share price is 60% less volatile than the S&P 500.
Electromed has lower revenue, but higher earnings than Outset Medical. Outset Medical is trading at a lower price-to-earnings ratio than Electromed, indicating that it is currently the more affordable of the two stocks.
Outset Medical received 9 more outperform votes than Electromed when rated by MarketBeat users. However, 86.67% of users gave Electromed an outperform vote while only 37.93% of users gave Outset Medical an outperform vote.
40.8% of Electromed shares are held by institutional investors. 3.5% of Outset Medical shares are held by company insiders. Comparatively, 12.7% of Electromed shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Outset Medical currently has a consensus target price of $5.42, suggesting a potential upside of 50.05%. Given Electromed's higher possible upside, equities analysts clearly believe Outset Medical is more favorable than Electromed.
Summary
Electromed beats Outset Medical on 11 of the 17 factors compared between the two stocks.
Get Electromed News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Electromed Competitors List
Related Companies and Tools
